JP2008502700A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008502700A5 JP2008502700A5 JP2007516703A JP2007516703A JP2008502700A5 JP 2008502700 A5 JP2008502700 A5 JP 2008502700A5 JP 2007516703 A JP2007516703 A JP 2007516703A JP 2007516703 A JP2007516703 A JP 2007516703A JP 2008502700 A5 JP2008502700 A5 JP 2008502700A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- imidazol
- substituted
- benzyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 carbocycle Chemical group 0.000 claims 144
- 125000000217 alkyl group Chemical group 0.000 claims 110
- 125000000623 heterocyclic group Chemical group 0.000 claims 101
- 125000005842 heteroatom Chemical group 0.000 claims 50
- 229910052760 oxygen Inorganic materials 0.000 claims 49
- 229910052739 hydrogen Inorganic materials 0.000 claims 45
- 229910052799 carbon Inorganic materials 0.000 claims 40
- 229910052717 sulfur Inorganic materials 0.000 claims 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 33
- 125000004432 carbon atom Chemical group C* 0.000 claims 32
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 28
- RSILLSRLAWUTAY-UHFFFAOYSA-N 4-(aminomethyl)cyclohexane-1-carboxamide Chemical compound NCC1CCC(C(N)=O)CC1 RSILLSRLAWUTAY-UHFFFAOYSA-N 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 22
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 18
- RSILLSRLAWUTAY-LJGSYFOKSA-N NC[C@H]1CC[C@H](C(N)=O)CC1 Chemical compound NC[C@H]1CC[C@H](C(N)=O)CC1 RSILLSRLAWUTAY-LJGSYFOKSA-N 0.000 claims 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000001721 carbon Chemical group 0.000 claims 16
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 14
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 12
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 11
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000004429 atom Chemical group 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000001624 naphthyl group Chemical group 0.000 claims 8
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 7
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 6
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 5
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 5
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 5
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 5
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 5
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 5
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000004537 indazol-5-yl group Chemical group N1N=CC2=CC(=CC=C12)* 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- KSWRJISIQSPBCJ-UHFFFAOYSA-N 2h-isoquinoline Chemical compound C1=CC=C2[CH]NC=CC2=C1 KSWRJISIQSPBCJ-UHFFFAOYSA-N 0.000 claims 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 claims 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- YDLAQBRNNOLMIH-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]formamide Chemical group ClC1=CC=C(CNC=O)C=C1 YDLAQBRNNOLMIH-UHFFFAOYSA-N 0.000 claims 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- YQMJBZVQZHKATR-GGAORHGYSA-N (6R)-1-amino-N-[(1S)-1-[5-chloro-4-(4-cyanophenyl)-1H-imidazol-2-yl]-2-phenylethyl]-5,6,7,8-tetrahydroisoquinoline-6-carboxamide Chemical compound C([C@H](NC(=O)[C@H]1CC=2C=CN=C(C=2CC1)N)C=1NC(Cl)=C(N=1)C=1C=CC(=CC=1)C#N)C1=CC=CC=C1 YQMJBZVQZHKATR-GGAORHGYSA-N 0.000 claims 1
- ICSJXVUUSDNFIJ-GCJKJVERSA-N (6r)-1-amino-n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-5,6,7,8-tetrahydroisoquinoline-6-carboxamide Chemical compound C([C@@H](C1=NC(=C(N1)Cl)C=1C=C2NN=C(C2=CC=1)N)NC(=O)[C@H]1CC2=CC=NC(N)=C2CC1)C1=CC=CC=C1 ICSJXVUUSDNFIJ-GCJKJVERSA-N 0.000 claims 1
- ICSJXVUUSDNFIJ-AVRDEDQJSA-N (6s)-1-amino-n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-5,6,7,8-tetrahydroisoquinoline-6-carboxamide Chemical compound C([C@@H](C1=NC(=C(N1)Cl)C=1C=C2NN=C(C2=CC=1)N)NC(=O)[C@@H]1CC2=CC=NC(N)=C2CC1)C1=CC=CC=C1 ICSJXVUUSDNFIJ-AVRDEDQJSA-N 0.000 claims 1
- YQMJBZVQZHKATR-GMAHTHKFSA-N (6s)-1-amino-n-[(1s)-1-[5-chloro-4-(4-cyanophenyl)-1h-imidazol-2-yl]-2-phenylethyl]-5,6,7,8-tetrahydroisoquinoline-6-carboxamide Chemical compound C([C@H](NC(=O)[C@@H]1CC=2C=CN=C(C=2CC1)N)C=1NC(Cl)=C(N=1)C=1C=CC(=CC=1)C#N)C1=CC=CC=C1 YQMJBZVQZHKATR-GMAHTHKFSA-N 0.000 claims 1
- ICSJXVUUSDNFIJ-HXBUSHRASA-N (6s)-1-amino-n-[1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-5,6,7,8-tetrahydroisoquinoline-6-carboxamide Chemical compound C=1C=C2C(N)=NNC2=CC=1C(=C(N1)Cl)N=C1C(NC(=O)[C@@H]1CC2=CC=NC(N)=C2CC1)CC1=CC=CC=C1 ICSJXVUUSDNFIJ-HXBUSHRASA-N 0.000 claims 1
- KNVDGWXWPWHPCC-HSTJUUNISA-N (6s)-1-amino-n-[1-[4-(4-aminoquinazolin-7-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-5,6,7,8-tetrahydroisoquinoline-6-carboxamide Chemical compound O=C([C@@H]1CC=2C=CN=C(C=2CC1)N)NC(C=1NC(Cl)=C(N=1)C=1C=C2N=CN=C(N)C2=CC=1)CC1=CC=CC=C1 KNVDGWXWPWHPCC-HSTJUUNISA-N 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- KCOPAESEGCGTKM-UHFFFAOYSA-N 1,3-oxazol-4-one Chemical class O=C1COC=N1 KCOPAESEGCGTKM-UHFFFAOYSA-N 0.000 claims 1
- XKNHFWHZDIOLSR-QHCPKHFHSA-N 1-amino-n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-3-methylisoquinoline-6-carboxamide Chemical compound C([C@H](NC(=O)C=1C=C2C=C(N=C(N)C2=CC=1)C)C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)C1=CC=CC=C1 XKNHFWHZDIOLSR-QHCPKHFHSA-N 0.000 claims 1
- KWHJKKRXFUNBAJ-QFIPXVFZSA-N 1-amino-n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]isoquinoline-6-carboxamide Chemical compound C([C@@H](C1=NC(=C(N1)Cl)C=1C=C2NN=C(C2=CC=1)N)NC(=O)C=1C=C2C=CN=C(N)C2=CC=1)C1=CC=CC=C1 KWHJKKRXFUNBAJ-QFIPXVFZSA-N 0.000 claims 1
- ZMUSBULBJACGQA-UHFFFAOYSA-N 1-n-[1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-2-chlorobenzene-1,4-dicarboxamide Chemical compound ClC1=CC(C(=O)N)=CC=C1C(=O)NC(C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 ZMUSBULBJACGQA-UHFFFAOYSA-N 0.000 claims 1
- ZBNZAJFNDPPMDT-UHFFFAOYSA-N 1h-imidazole-5-carboxamide Chemical compound NC(=O)C1=CNC=N1 ZBNZAJFNDPPMDT-UHFFFAOYSA-N 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- WWUIZLHTDBGHFH-UHFFFAOYSA-N 2-[5-(4-carbamimidoylphenyl)-1h-imidazol-2-yl]-n,3-diphenylpropanamide Chemical compound C1=CC(C(=N)N)=CC=C1C1=CNC(C(CC=2C=CC=CC=2)C(=O)NC=2C=CC=CC=2)=N1 WWUIZLHTDBGHFH-UHFFFAOYSA-N 0.000 claims 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000004352 2-phenylcyclohexyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- PKSAIJQAOZGOKV-IBGZPJMESA-N 3-amino-n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-1,2-benzoxazole-6-carboxamide Chemical compound C([C@@H](C1=NC(=C(N1)Cl)C=1C=C2NN=C(C2=CC=1)N)NC(=O)C=1C=C2ON=C(N)C2=CC=1)C1=CC=CC=C1 PKSAIJQAOZGOKV-IBGZPJMESA-N 0.000 claims 1
- IAJDAQJCIKJYEG-FQEVSTJZSA-N 3-amino-n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-1h-indazole-5-carboxamide Chemical compound C([C@@H](C1=NC(=C(N1)Cl)C=1C=C2NN=C(C2=CC=1)N)NC(=O)C=1C=C2C(N)=NNC2=CC=1)C1=CC=CC=C1 IAJDAQJCIKJYEG-FQEVSTJZSA-N 0.000 claims 1
- QEDSKDDUNJZZHC-FQEVSTJZSA-N 3-amino-n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-1h-indazole-6-carboxamide Chemical compound C([C@H](NC(=O)C=1C=C2NN=C(C2=CC=1)N)C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)C1=CC=CC=C1 QEDSKDDUNJZZHC-FQEVSTJZSA-N 0.000 claims 1
- YVUNSWOVNWOOSB-NRFANRHFSA-N 3-amino-n-[(1s)-1-[5-(4-carbamimidoylphenyl)-1h-imidazol-2-yl]-2-phenylethyl]-1h-indazole-5-carboxamide Chemical compound C1=CC(C(=N)N)=CC=C1C1=CNC([C@H](CC=2C=CC=CC=2)NC(=O)C=2C=C3C(N)=NNC3=CC=2)=N1 YVUNSWOVNWOOSB-NRFANRHFSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- OXMAFNHUBUZZQD-GRERDSQWSA-N 4-(aminomethyl)-n-[(1s)-1-[5-(1,3-benzodioxol-5-yl)-1h-imidazol-2-yl]-2-phenylethyl]cyclohexane-1-carboxamide Chemical compound C1CC(CN)CCC1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2OCOC2=CC=1)CC1=CC=CC=C1 OXMAFNHUBUZZQD-GRERDSQWSA-N 0.000 claims 1
- XFUJSTYMHFWPGW-AJTFCVKESA-N 4-(aminomethyl)-n-[(1s)-1-[5-(3-aminophenyl)-1h-imidazol-2-yl]-2-phenylethyl]cyclohexane-1-carboxamide Chemical compound C1CC(CN)CCC1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C(N)C=CC=1)CC1=CC=CC=C1 XFUJSTYMHFWPGW-AJTFCVKESA-N 0.000 claims 1
- HROQHIMMOVNTMW-QFIPXVFZSA-N 4-(aminomethyl)-n-[(1s)-1-[5-(4-carbamoylphenyl)-1h-imidazol-2-yl]-2-phenylethyl]-2-fluorobenzamide Chemical compound FC1=CC(CN)=CC=C1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(=CC=1)C(N)=O)CC1=CC=CC=C1 HROQHIMMOVNTMW-QFIPXVFZSA-N 0.000 claims 1
- MASSIHFRZVOSGL-QFIPXVFZSA-N 4-(aminomethyl)-n-[(1s)-1-[5-(4-carbamoylphenyl)-1h-imidazol-2-yl]-2-phenylethyl]benzamide Chemical compound C1=CC(CN)=CC=C1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(=CC=1)C(N)=O)CC1=CC=CC=C1 MASSIHFRZVOSGL-QFIPXVFZSA-N 0.000 claims 1
- ZEJLTWLVGBBHBH-FYPSYCSSSA-N 4-[(1S)-1-[4-(4-aminoquinazolin-7-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl]-3-fluorocyclohexa-1,5-diene-1,4-dicarboxamide Chemical compound NC1=NC=NC2=CC(=CC=C12)C=1N=C(NC1Cl)[C@@H](CC1=CC=CC=C1)C1(C(=O)N)C(C=C(C(=O)N)C=C1)F ZEJLTWLVGBBHBH-FYPSYCSSSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- YOBXSQWDCHADCX-FQEVSTJZSA-N 4-n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]benzene-1,4-dicarboxamide Chemical compound C1=CC(C(=O)N)=CC=C1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 YOBXSQWDCHADCX-FQEVSTJZSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- XMVSNHIHOXNDAY-YDHSSHFGSA-N C([C@@H](C=1NC(=C(N=1)C=1C=C2NN=C(N)C2=CC=1)C)NC(=O)[C@@H]1CC[C@@H](CN)CC1)C1=CC=CC=C1 Chemical compound C([C@@H](C=1NC(=C(N=1)C=1C=C2NN=C(N)C2=CC=1)C)NC(=O)[C@@H]1CC[C@@H](CN)CC1)C1=CC=CC=C1 XMVSNHIHOXNDAY-YDHSSHFGSA-N 0.000 claims 1
- SFZTUAGLDAGVMT-SKPFHBQLSA-N C([C@@H](C=1NC(=C(N=1)C=1C=C2NN=CC2=CC=1)C)NC(=O)[C@@H]1CC[C@@H](CN)CC1)C1=CC=CC=C1 Chemical compound C([C@@H](C=1NC(=C(N=1)C=1C=C2NN=CC2=CC=1)C)NC(=O)[C@@H]1CC[C@@H](CN)CC1)C1=CC=CC=C1 SFZTUAGLDAGVMT-SKPFHBQLSA-N 0.000 claims 1
- UFUGDJYBDKSJHA-LRKVRUBVSA-N C([C@@]1(C)OC2=C(CC(NC(=O)[C@@H]3CC[C@@H](CN)CC3)C=3NC=C(N=3)C=3C=C4NN=C(N)C4=CC=3)C=CC=C2O1)CC1=CC=CC=C1 Chemical compound C([C@@]1(C)OC2=C(CC(NC(=O)[C@@H]3CC[C@@H](CN)CC3)C=3NC=C(N=3)C=3C=C4NN=C(N)C4=CC=3)C=CC=C2O1)CC1=CC=CC=C1 UFUGDJYBDKSJHA-LRKVRUBVSA-N 0.000 claims 1
- UFUGDJYBDKSJHA-ARWOVHFBSA-N C([C@]1(C)OC2=C(CC(NC(=O)[C@@H]3CC[C@@H](CN)CC3)C=3NC=C(N=3)C=3C=C4NN=C(N)C4=CC=3)C=CC=C2O1)CC1=CC=CC=C1 Chemical compound C([C@]1(C)OC2=C(CC(NC(=O)[C@@H]3CC[C@@H](CN)CC3)C=3NC=C(N=3)C=3C=C4NN=C(N)C4=CC=3)C=CC=C2O1)CC1=CC=CC=C1 UFUGDJYBDKSJHA-ARWOVHFBSA-N 0.000 claims 1
- XBGNYYYPYHVNCH-RSEQLOHWSA-N C1=CC(NC(=O)C)=CC=C1C1=C(C)NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=N1 Chemical compound C1=CC(NC(=O)C)=CC=C1C1=C(C)NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=N1 XBGNYYYPYHVNCH-RSEQLOHWSA-N 0.000 claims 1
- DHIHJHBYWNQABC-VIQNHZKISA-N C1=CC(NC(=O)OC)=CC=C1C1=C(C)NC(C(CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=N1 Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=C(C)NC(C(CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=N1 DHIHJHBYWNQABC-VIQNHZKISA-N 0.000 claims 1
- VRZJJSKJFUCUHX-RRPUWOKSSA-N C1=CC(OC)=CC=C1C1=CNC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=N1 Chemical compound C1=CC(OC)=CC=C1C1=CNC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=N1 VRZJJSKJFUCUHX-RRPUWOKSSA-N 0.000 claims 1
- SZQZCQKMZHGHRO-MCPCIJHBSA-N C1=CC=C(C=C1)C[C@H](C2=NC(=C(N2)Cl)C3=CC4=C(C=C3)C(=NN4)N)C5(C=CC(=CC5F)C(=O)N)C(=O)N Chemical compound C1=CC=C(C=C1)C[C@H](C2=NC(=C(N2)Cl)C3=CC4=C(C=C3)C(=NN4)N)C5(C=CC(=CC5F)C(=O)N)C(=O)N SZQZCQKMZHGHRO-MCPCIJHBSA-N 0.000 claims 1
- PMPZBVXOHYLBLZ-CCCGKPSOSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(OC(F)F)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(OC(F)F)=C1 PMPZBVXOHYLBLZ-CCCGKPSOSA-N 0.000 claims 1
- QZJGBVKZKVXKDI-UYJZDEDHSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CCC(=O)NCC1=CC=CC=N1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CCC(=O)NCC1=CC=CC=N1 QZJGBVKZKVXKDI-UYJZDEDHSA-N 0.000 claims 1
- PBADOZCAKMTDRZ-OSPTYYIOSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CCC(=O)NCC1=NC=CS1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CCC(=O)NCC1=NC=CS1 PBADOZCAKMTDRZ-OSPTYYIOSA-N 0.000 claims 1
- CGWMVOBUPNPZBP-BDWYFLKXSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC(Cl)=C(N=1)C=1SC(=CC=1)C(O)=O)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC(Cl)=C(N=1)C=1SC(=CC=1)C(O)=O)CC1=CC=CC=C1 CGWMVOBUPNPZBP-BDWYFLKXSA-N 0.000 claims 1
- GZPCYIOWDKNNAC-VRXNAAEZSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(OC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(OC=2C=CC=CC=2)=C1 GZPCYIOWDKNNAC-VRXNAAEZSA-N 0.000 claims 1
- DCHGPEHFBMCAHD-DDLDZWDOSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1OC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1OC1=CC=CC=C1 DCHGPEHFBMCAHD-DDLDZWDOSA-N 0.000 claims 1
- KDTNBPJFLDIYKY-FAHCRBBMSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1OCC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)NC(C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1OCC1=CC=CC=C1 KDTNBPJFLDIYKY-FAHCRBBMSA-N 0.000 claims 1
- LMOLSRBKSQPPEE-FIXSFTCYSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1N(C=CN=1)C=1C=CC(CC(N)=O)=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1N(C=CN=1)C=1C=CC(CC(N)=O)=CC=1)CC1=CC=CC=C1 LMOLSRBKSQPPEE-FIXSFTCYSA-N 0.000 claims 1
- HHDMHGSDQNXXKT-OSOCVKALSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(=C(N=1)C=1C=C2NN=C(N)C2=CC=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(=C(N=1)C=1C=C2NN=C(N)C2=CC=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 HHDMHGSDQNXXKT-OSOCVKALSA-N 0.000 claims 1
- OXOUMULEBUAKGY-KNBMTAEXSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(=CN=1)C=1C=C2NN=C(N)C2=CC=1)CCC(=O)NCC1CC1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(=CN=1)C=1C=C2NN=C(N)C2=CC=1)CCC(=O)NCC1CC1 OXOUMULEBUAKGY-KNBMTAEXSA-N 0.000 claims 1
- SVBQAWLFJJJYAF-HFMPRLQTSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(=CN=1)C=1C=C2NN=C(N)C2=CC=1)CCC(=O)NCCC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(=CN=1)C=1C=C2NN=C(N)C2=CC=1)CCC(=O)NCCC1=CC=CC=C1 SVBQAWLFJJJYAF-HFMPRLQTSA-N 0.000 claims 1
- APTJCYRDVQGYKJ-FIKGOQFSSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Br)=C(N=1)C=1C=C(F)C(C(N)=O)=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Br)=C(N=1)C=1C=C(F)C(C(N)=O)=CC=1)CC1=CC=CC=C1 APTJCYRDVQGYKJ-FIKGOQFSSA-N 0.000 claims 1
- FVSBUODBQHEOBR-FIKGOQFSSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Br)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Br)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 FVSBUODBQHEOBR-FIKGOQFSSA-N 0.000 claims 1
- VNAXCPLZKUCQEN-BXWFABGCSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C(=C2NN=C(N)C2=CC=1)F)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C(=C2NN=C(N)C2=CC=1)F)CC1=CC=CC=C1 VNAXCPLZKUCQEN-BXWFABGCSA-N 0.000 claims 1
- SZZLPZZLIPNJKK-QYWGDWMGSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C(=CC=2C(N)=NNC=2C=1)F)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C(=CC=2C(N)=NNC=2C=1)F)CC1=CC=CC=C1 SZZLPZZLIPNJKK-QYWGDWMGSA-N 0.000 claims 1
- FWPDOSQZOPMDNT-FIKGOQFSSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C(F)C(C(N)=O)=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C(F)C(C(N)=O)=CC=1)CC1=CC=CC=C1 FWPDOSQZOPMDNT-FIKGOQFSSA-N 0.000 claims 1
- UITWZKLQPJTEBS-FIKGOQFSSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2N=C(N)N=C(N)C2=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2N=C(N)N=C(N)C2=CC=1)CC1=CC=CC=C1 UITWZKLQPJTEBS-FIKGOQFSSA-N 0.000 claims 1
- KRZVIILFMQGKNG-SPEDKVCISA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2N=CN=C(N)C2=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2N=CN=C(N)C2=CC=1)CC1=CC=CC=C1 KRZVIILFMQGKNG-SPEDKVCISA-N 0.000 claims 1
- PUEAGZRUQZQUMS-FTRWYGJKSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=C(F)C=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=C(F)C=1)CC1=CC=CC=C1 PUEAGZRUQZQUMS-FTRWYGJKSA-N 0.000 claims 1
- IHWCFYRASOTRPD-NJVGLYJLSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 IHWCFYRASOTRPD-NJVGLYJLSA-N 0.000 claims 1
- IOLSRAXZCKDSPO-FIKGOQFSSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 IOLSRAXZCKDSPO-FIKGOQFSSA-N 0.000 claims 1
- SCRQGBZGJTUXQT-SPEDKVCISA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C(=CC(F)=CC=1)F)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C(=CC(F)=CC=1)F)CC1=CC=CC=C1 SCRQGBZGJTUXQT-SPEDKVCISA-N 0.000 claims 1
- FDIRLVFXSQLMCK-IPJJNNNSSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C(Br)C=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C(Br)C=CC=1)CC1=CC=CC=C1 FDIRLVFXSQLMCK-IPJJNNNSSA-N 0.000 claims 1
- YUYASEADSWBPJG-IPJJNNNSSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C(F)C=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C(F)C=CC=1)CC1=CC=CC=C1 YUYASEADSWBPJG-IPJJNNNSSA-N 0.000 claims 1
- HOHAHIWCEXRECM-IPJJNNNSSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C(O)C=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C(O)C=CC=1)CC1=CC=CC=C1 HOHAHIWCEXRECM-IPJJNNNSSA-N 0.000 claims 1
- YXKLVKFYPGRVFV-SPEDKVCISA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2C(N)=NNC2=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2C(N)=NNC2=CC=1)CC1=CC=CC=C1 YXKLVKFYPGRVFV-SPEDKVCISA-N 0.000 claims 1
- JEGVFZHQXZGMEO-SPEDKVCISA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2C(O)=NNC2=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2C(O)=NNC2=CC=1)CC1=CC=CC=C1 JEGVFZHQXZGMEO-SPEDKVCISA-N 0.000 claims 1
- XBKHIWABLDTJLJ-KJOQGJGQSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2C=CC=CC2=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2C=CC=CC2=CC=1)CC1=CC=CC=C1 XBKHIWABLDTJLJ-KJOQGJGQSA-N 0.000 claims 1
- VVMVKSKSVOIEKI-GTFGCAHESA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(C=2C=CC=CC=2)=C1 VVMVKSKSVOIEKI-GTFGCAHESA-N 0.000 claims 1
- AEOMRGHHYBBVMU-YHEJKZAPSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(N)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(N)=C1 AEOMRGHHYBBVMU-YHEJKZAPSA-N 0.000 claims 1
- BUUAPBNZVUOGGJ-AHPZTNMXSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 BUUAPBNZVUOGGJ-AHPZTNMXSA-N 0.000 claims 1
- OWEXKSPHKPAERJ-YHEJKZAPSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC([N+]([O-])=O)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC([N+]([O-])=O)=C1 OWEXKSPHKPAERJ-YHEJKZAPSA-N 0.000 claims 1
- OZUSOKUTOILBQQ-WCJKSRRJSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1Br Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1Br OZUSOKUTOILBQQ-WCJKSRRJSA-N 0.000 claims 1
- MRWSWULIHWSBRC-AHPZTNMXSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1C1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1C1=CC=CC=C1 MRWSWULIHWSBRC-AHPZTNMXSA-N 0.000 claims 1
- NFSRBUVLFLSXSR-WCJKSRRJSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1N Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1N NFSRBUVLFLSXSR-WCJKSRRJSA-N 0.000 claims 1
- MCVAVMKVGWVZSL-QYWGDWMGSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1[N+]([O-])=O Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1[N+]([O-])=O MCVAVMKVGWVZSL-QYWGDWMGSA-N 0.000 claims 1
- VYCGOBREHCWYNU-KDLAUNOPSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)COCC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)COCC1=CC=CC=C1 VYCGOBREHCWYNU-KDLAUNOPSA-N 0.000 claims 1
- KNVDKCZDLKERMV-KDLAUNOPSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CSCC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CSCC1=CC=CC=C1 KNVDKCZDLKERMV-KDLAUNOPSA-N 0.000 claims 1
- OIKBNFXMDIXXEK-PMVMPFDFSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(=CC=1)C#N)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(=CC=1)C#N)CC1=CC=CC=C1 OIKBNFXMDIXXEK-PMVMPFDFSA-N 0.000 claims 1
- ZPOKVPJNNYWABA-RNCAPKPVSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 ZPOKVPJNNYWABA-RNCAPKPVSA-N 0.000 claims 1
- PAORIEKZTQOHFI-VCOUNFBDSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(Br)=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(Br)=CC=1)CC1=CC=CC=C1 PAORIEKZTQOHFI-VCOUNFBDSA-N 0.000 claims 1
- OPEBKTYGAAFDNT-VCOUNFBDSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(F)=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(F)=CC=1)CC1=CC=CC=C1 OPEBKTYGAAFDNT-VCOUNFBDSA-N 0.000 claims 1
- OHIQWBQFJDZDPT-KMDNEMHUSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(OCC=2C=CC=CC=2)=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC(OCC=2C=CC=CC=2)=CC=1)CC1=CC=CC=C1 OHIQWBQFJDZDPT-KMDNEMHUSA-N 0.000 claims 1
- QUCZLDXMCRVHMD-KMDNEMHUSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC(C=C1)=CC=C1OCC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC(C=C1)=CC=C1OCC1=CC=CC=C1 QUCZLDXMCRVHMD-KMDNEMHUSA-N 0.000 claims 1
- ZFIDKNFHOLUHAM-CVJWPJSTSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC(N=C1)=CN1CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC(N=C1)=CN1CC1=CC=CC=C1 ZFIDKNFHOLUHAM-CVJWPJSTSA-N 0.000 claims 1
- ZFNSUYFPEWTHIZ-RNCAPKPVSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=C(C(=O)C=2C=CC=CC=2)C=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=C(C(=O)C=2C=CC=CC=2)C=C1 ZFNSUYFPEWTHIZ-RNCAPKPVSA-N 0.000 claims 1
- LWWOEYFHTRCMHK-RJWMVNQGSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=C(C=CC=C2)C2=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=C(C=CC=C2)C2=C1 LWWOEYFHTRCMHK-RJWMVNQGSA-N 0.000 claims 1
- YEQJKQBTFAUBTJ-VCOUNFBDSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=C(Cl)C=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=C(Cl)C=C1 YEQJKQBTFAUBTJ-VCOUNFBDSA-N 0.000 claims 1
- CCWUEFYOTWVESF-VCOUNFBDSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=C(F)C=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=C(F)C=C1 CCWUEFYOTWVESF-VCOUNFBDSA-N 0.000 claims 1
- MEDPYAMKRQXIDL-XJABCFGWSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC(C(F)(F)F)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC(C(F)(F)F)=C1 MEDPYAMKRQXIDL-XJABCFGWSA-N 0.000 claims 1
- KWMFIROBLSTTJU-XJABCFGWSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC(Cl)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC(Cl)=C1 KWMFIROBLSTTJU-XJABCFGWSA-N 0.000 claims 1
- YSKRCHAGPUFMSQ-XJABCFGWSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC([N+]([O-])=O)=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC([N+]([O-])=O)=C1 YSKRCHAGPUFMSQ-XJABCFGWSA-N 0.000 claims 1
- ITWYAKIFKGNDSS-CHZKFRDHSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC2=CC=CC=C12 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC2=CC=CC=C12 ITWYAKIFKGNDSS-CHZKFRDHSA-N 0.000 claims 1
- TWAXLYHFTMDLNJ-BVSLBCMMSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1 TWAXLYHFTMDLNJ-BVSLBCMMSA-N 0.000 claims 1
- RZBXXGSVODAHBN-JLMWRMLUSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1Br Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1Br RZBXXGSVODAHBN-JLMWRMLUSA-N 0.000 claims 1
- HDDLJGWNRBEEKJ-JLMWRMLUSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1Cl Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=C1Cl HDDLJGWNRBEEKJ-JLMWRMLUSA-N 0.000 claims 1
- ZIZJZSJDMNBAAY-CUWPLCDZSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=N1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=CC=N1 ZIZJZSJDMNBAAY-CUWPLCDZSA-N 0.000 claims 1
- HNKOKPXMHPMWCO-JBACZVJFSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=NC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1C=CC=CC=1)CC1=CC=NC=C1 HNKOKPXMHPMWCO-JBACZVJFSA-N 0.000 claims 1
- MNHPXVXRSFNURX-ZJOUEHCJSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1N=CC=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1N=CC=CC=1)CC1=CC=CC=C1 MNHPXVXRSFNURX-ZJOUEHCJSA-N 0.000 claims 1
- VKXRVCPAICCKNT-BZSNNMDCSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1SC=CN=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)N[C@H](C=1NC=C(N=1)C=1SC=CN=1)CC1=CC=CC=C1 VKXRVCPAICCKNT-BZSNNMDCSA-N 0.000 claims 1
- LPIGZMVVKVUVJT-RFJGZHNSSA-N CC(=O)NC1=CC=CC(C2=C(NC(=N2)C(CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)C)=C1 Chemical compound CC(=O)NC1=CC=CC(C2=C(NC(=N2)C(CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)C)=C1 LPIGZMVVKVUVJT-RFJGZHNSSA-N 0.000 claims 1
- AUHKAVIGSUNLAC-PBVHZTIHSA-N CC=1NC(C(CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C(C=1)=CC=CC=1C=1N=NNN=1 Chemical compound CC=1NC(C(CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C(C=1)=CC=CC=1C=1N=NNN=1 AUHKAVIGSUNLAC-PBVHZTIHSA-N 0.000 claims 1
- QULCFOVPBNGKHP-VJBMBRPKSA-N CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=C(C(N)=O)C=C1 Chemical compound CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=C(C(N)=O)C=C1 QULCFOVPBNGKHP-VJBMBRPKSA-N 0.000 claims 1
- PGBVMKSRGXWUPW-ZJOUEHCJSA-N CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=C(N)N=C1 Chemical compound CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=C(N)N=C1 PGBVMKSRGXWUPW-ZJOUEHCJSA-N 0.000 claims 1
- AZCCEANPCOKCEZ-SSPYTLHUSA-N CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=C(NS(C)(=O)=O)C=C1 Chemical compound CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=C(NS(C)(=O)=O)C=C1 AZCCEANPCOKCEZ-SSPYTLHUSA-N 0.000 claims 1
- VRXYRXWLGLMSOM-RRPUWOKSSA-N CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=C(O)C=C1 Chemical compound CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=C(O)C=C1 VRXYRXWLGLMSOM-RRPUWOKSSA-N 0.000 claims 1
- WKTYEJOQGHCJQG-JTAQYXEDSA-N CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=CC(Cl)=C1 Chemical compound CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=CC(Cl)=C1 WKTYEJOQGHCJQG-JTAQYXEDSA-N 0.000 claims 1
- JKMYMDKYJLLHFS-PMVMPFDFSA-N CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=CC=C1 Chemical compound CC=1NC([C@H](CC=2C=CC=CC=2)NC(=O)[C@@H]2CC[C@@H](CN)CC2)=NC=1C1=CC=CC=C1 JKMYMDKYJLLHFS-PMVMPFDFSA-N 0.000 claims 1
- UOIACFBLJVJENH-XZATXCMXSA-N COC1=C(C=CC(C1)([C@H](CC2=CC=CC=C2)C3=NC(=C(N3)Cl)C4=CC5=C(C=C4)C(=NN5)N)C(=O)N)C(=O)N Chemical compound COC1=C(C=CC(C1)([C@H](CC2=CC=CC=C2)C3=NC(=C(N3)Cl)C4=CC5=C(C=C4)C(=NN5)N)C(=O)N)C(=O)N UOIACFBLJVJENH-XZATXCMXSA-N 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010014513 Embolism arterial Diseases 0.000 claims 1
- JZYNYQIQDBFMMC-HOIFWPIMSA-N N([C@@H](CC=1C=CC=C2OC(OC2=1)(C)C)C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)C(=O)[C@H]1CC[C@H](CN)CC1 Chemical compound N([C@@H](CC=1C=CC=C2OC(OC2=1)(C)C)C=1NC=C(N=1)C=1C=C2NN=C(N)C2=CC=1)C(=O)[C@H]1CC[C@H](CN)CC1 JZYNYQIQDBFMMC-HOIFWPIMSA-N 0.000 claims 1
- HYSLPWIHYONTBX-OPYUEGPBSA-N N=1C(C=2C=C3C(=O)NCC3=CC=2)=C(C)NC=1C(NC(=O)[C@@H]1CC[C@@H](CN)CC1)CC1=CC=CC=C1 Chemical compound N=1C(C=2C=C3C(=O)NCC3=CC=2)=C(C)NC=1C(NC(=O)[C@@H]1CC[C@@H](CN)CC1)CC1=CC=CC=C1 HYSLPWIHYONTBX-OPYUEGPBSA-N 0.000 claims 1
- RLYOTNMLYVAKSH-CIQKOQMRSA-N N=1C(C=2C=C3C(C(NNC3=O)=N)=CC=2)=C(C)NC=1C(NC(=O)[C@@H]1CC[C@@H](CN)CC1)CC1=CC=CC=C1 Chemical compound N=1C(C=2C=C3C(C(NNC3=O)=N)=CC=2)=C(C)NC=1C(NC(=O)[C@@H]1CC[C@@H](CN)CC1)CC1=CC=CC=C1 RLYOTNMLYVAKSH-CIQKOQMRSA-N 0.000 claims 1
- SFZTUAGLDAGVMT-OPYUEGPBSA-N N=1C(C=2C=C3NN=CC3=CC=2)=C(C)NC=1C(NC(=O)[C@@H]1CC[C@@H](CN)CC1)CC1=CC=CC=C1 Chemical compound N=1C(C=2C=C3NN=CC3=CC=2)=C(C)NC=1C(NC(=O)[C@@H]1CC[C@@H](CN)CC1)CC1=CC=CC=C1 SFZTUAGLDAGVMT-OPYUEGPBSA-N 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000028922 artery disease Diseases 0.000 claims 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 claims 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 208000002528 coronary thrombosis Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 1
- FPEVUBJUBWMQAV-QHCPKHFHSA-N n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-1,2,3,4-tetrahydroisoquinoline-6-carboxamide Chemical compound C([C@@H](C1=NC(=C(N1)Cl)C=1C=C2NN=C(C2=CC=1)N)NC(=O)C=1C=C2CCNCC2=CC=1)C1=CC=CC=C1 FPEVUBJUBWMQAV-QHCPKHFHSA-N 0.000 claims 1
- NZDPXJITCXXVCM-QFIPXVFZSA-N n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-1-oxo-2h-isoquinoline-6-carboxamide Chemical compound C([C@@H](C1=NC(=C(N1)Cl)C=1C=C2NN=C(C2=CC=1)N)NC(=O)C=1C=C2C(C(NC=C2)=O)=CC=1)C1=CC=CC=C1 NZDPXJITCXXVCM-QFIPXVFZSA-N 0.000 claims 1
- GPRFRPSBAQFJDF-QFIPXVFZSA-N n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-1-oxo-3,4-dihydro-2h-isoquinoline-6-carboxamide Chemical compound C([C@@H](C1=NC(=C(N1)Cl)C=1C=C2NN=C(C2=CC=1)N)NC(=O)C=1C=C2CCNC(=O)C2=CC=1)C1=CC=CC=C1 GPRFRPSBAQFJDF-QFIPXVFZSA-N 0.000 claims 1
- INTVALDREIMOQM-NRFANRHFSA-N n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-2-fluoro-5-methoxybenzamide Chemical compound COC1=CC=C(F)C(C(=O)N[C@@H](CC=2C=CC=CC=2)C=2NC(Cl)=C(N=2)C=2C=C3NN=C(N)C3=CC=2)=C1 INTVALDREIMOQM-NRFANRHFSA-N 0.000 claims 1
- MLRWRXLIKMFNTF-NDEPHWFRSA-N n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-4-(aminomethyl)-2-benzylbenzamide Chemical compound C([C@H](NC(=O)C1=CC=C(C=C1CC=1C=CC=CC=1)CN)C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)C1=CC=CC=C1 MLRWRXLIKMFNTF-NDEPHWFRSA-N 0.000 claims 1
- SXHMJNGJPFLPLF-NRFANRHFSA-N n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-4-(aminomethyl)-2-fluorobenzamide Chemical compound FC1=CC(CN)=CC=C1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 SXHMJNGJPFLPLF-NRFANRHFSA-N 0.000 claims 1
- QEAGMDVPYSGGAS-NRFANRHFSA-N n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-4-(aminomethyl)benzamide Chemical compound C1=CC(CN)=CC=C1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 QEAGMDVPYSGGAS-NRFANRHFSA-N 0.000 claims 1
- ZKWAXFOIXSJGTJ-NRFANRHFSA-N n-[(1s)-1-[4-(3-amino-1h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)N[C@H](C=1NC(Cl)=C(N=1)C=1C=C2NN=C(N)C2=CC=1)CC1=CC=CC=C1 ZKWAXFOIXSJGTJ-NRFANRHFSA-N 0.000 claims 1
- ONSXAUWGMUXDIQ-QHCPKHFHSA-N n-[(1s)-1-[4-(4-carbamimidoylphenyl)-1-ethylimidazol-2-yl]-2-phenylethyl]benzamide Chemical compound C([C@@H](C1=NC(=CN1CC)C=1C=CC(=CC=1)C(N)=N)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 ONSXAUWGMUXDIQ-QHCPKHFHSA-N 0.000 claims 1
- HMOMOTNEBKIQEO-QFIPXVFZSA-N n-[(1s)-1-[4-(4-carbamimidoylphenyl)-1-methylimidazol-2-yl]-2-phenylethyl]benzamide Chemical compound C([C@@H](C1=NC(=CN1C)C=1C=CC(=CC=1)C(N)=N)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 HMOMOTNEBKIQEO-QFIPXVFZSA-N 0.000 claims 1
- NOUHXHNFSMPYBP-PXLSRWGNSA-N n-[(1s)-1-[5-(3-amino-1h-indazol-6-yl)-1h-imidazol-2-yl]-4-(benzylamino)-4-oxobutyl]-4-(aminomethyl)cyclohexane-1-carboxamide Chemical compound C1CC(CN)CCC1C(=O)N[C@H](C=1NC(=CN=1)C=1C=C2NN=C(N)C2=CC=1)CCC(=O)NCC1=CC=CC=C1 NOUHXHNFSMPYBP-PXLSRWGNSA-N 0.000 claims 1
- KRXIFLREGAPDHE-IRZJEQJZSA-N n-[(1s)-1-[5-(3-amino-1h-indazol-6-yl)-1h-imidazol-2-yl]-4-[(5-methylpyrazin-2-yl)methylamino]-4-oxobutyl]-4-(aminomethyl)cyclohexane-1-carboxamide Chemical compound C1=NC(C)=CN=C1CNC(=O)CC[C@@H](C=1NC(=CN=1)C=1C=C2NN=C(N)C2=CC=1)NC(=O)C1CCC(CN)CC1 KRXIFLREGAPDHE-IRZJEQJZSA-N 0.000 claims 1
- BYMZQFRYGNATEK-HQOBLLPJSA-N n-[(1s)-1-[5-(3-amino-1h-indazol-6-yl)-1h-imidazol-2-yl]-4-[benzyl(methyl)amino]-4-oxobutyl]-4-(aminomethyl)cyclohexane-1-carboxamide Chemical compound C([C@H](NC(=O)C1CCC(CN)CC1)C=1NC(=CN=1)C=1C=C2NN=C(N)C2=CC=1)CC(=O)N(C)CC1=CC=CC=C1 BYMZQFRYGNATEK-HQOBLLPJSA-N 0.000 claims 1
- HDPAWKKAGADBEQ-QFIPXVFZSA-N n-[(1s)-1-[5-(4-carbamimidoylphenyl)-1h-imidazol-2-yl]-2-phenylethyl]-1h-indazole-6-carboxamide Chemical compound C1=CC(C(=N)N)=CC=C1C1=CNC([C@H](CC=2C=CC=CC=2)NC(=O)C=2C=C3NN=CC3=CC=2)=N1 HDPAWKKAGADBEQ-QFIPXVFZSA-N 0.000 claims 1
- AZKBLOTXRUYVCR-QHCPKHFHSA-N n-[(1s)-1-[5-(4-carbamimidoylphenyl)-1h-imidazol-2-yl]-2-phenylethyl]-1h-indole-6-carboxamide Chemical compound C1=CC(C(=N)N)=CC=C1C1=CNC([C@H](CC=2C=CC=CC=2)NC(=O)C=2C=C3NC=CC3=CC=2)=N1 AZKBLOTXRUYVCR-QHCPKHFHSA-N 0.000 claims 1
- MMARSDSMJMHKLL-NRFANRHFSA-N n-[(1s)-1-[5-(4-carbamimidoylphenyl)-1h-imidazol-2-yl]-2-phenylethyl]benzamide Chemical compound C1=CC(C(=N)N)=CC=C1C1=CNC([C@H](CC=2C=CC=CC=2)NC(=O)C=2C=CC=CC=2)=N1 MMARSDSMJMHKLL-NRFANRHFSA-N 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 201000005060 thrombophlebitis Diseases 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 C*c(cc1)cc(COc2ccccc2)c1C(N)=* Chemical compound C*c(cc1)cc(COc2ccccc2)c1C(N)=* 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57963804P | 2004-06-15 | 2004-06-15 | |
| US60/579,638 | 2004-06-15 | ||
| US68412705P | 2005-05-24 | 2005-05-24 | |
| US60/684,127 | 2005-05-24 | ||
| US11/151,667 US7453002B2 (en) | 2004-06-15 | 2005-06-13 | Five-membered heterocycles useful as serine protease inhibitors |
| US11/151,667 | 2005-06-13 | ||
| PCT/US2005/021212 WO2005123050A2 (en) | 2004-06-15 | 2005-06-14 | Five-membered heterocycles useful as serine protease inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008502700A JP2008502700A (ja) | 2008-01-31 |
| JP2008502700A5 true JP2008502700A5 (https=) | 2008-05-29 |
| JP4791460B2 JP4791460B2 (ja) | 2011-10-12 |
Family
ID=35481430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516703A Expired - Fee Related JP4791460B2 (ja) | 2004-06-15 | 2005-06-14 | セリンプロテアーゼ阻害剤として有用な５員複素環 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US7453002B2 (https=) |
| EP (1) | EP1773786B1 (https=) |
| JP (1) | JP4791460B2 (https=) |
| KR (1) | KR20070024601A (https=) |
| AU (1) | AU2005254102A1 (https=) |
| BR (1) | BRPI0512084A (https=) |
| CA (1) | CA2570472A1 (https=) |
| ES (1) | ES2628279T3 (https=) |
| IL (1) | IL179844A0 (https=) |
| MX (1) | MXPA06014642A (https=) |
| NO (1) | NO20065864L (https=) |
| RU (1) | RU2007101073A (https=) |
| WO (1) | WO2005123050A2 (https=) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7453002B2 (en) * | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US8143425B2 (en) * | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| WO2006076575A2 (en) * | 2005-01-13 | 2006-07-20 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor xia inhibitors |
| WO2006089005A2 (en) * | 2005-02-17 | 2006-08-24 | Bristol-Myers Squibb Company | Combination of selective factor viia and/or xia and plasma kallikrein inhibitors |
| WO2007007588A1 (ja) * | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| WO2007008942A2 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases |
| WO2007008926A1 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
| WO2007070816A2 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Thiophene derivatives as factor xia inhibitors |
| EP1981854B1 (en) * | 2005-12-14 | 2011-06-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| AU2006325746A1 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2007076161A2 (en) * | 2005-12-27 | 2007-07-05 | Myriad Genetics, Inc | Compounds with therapeutic activity |
| MY146623A (en) * | 2006-05-16 | 2012-09-14 | Boehringer Ingelheim Int | Substituted prolinamides, manufacturing, and the use thereof as medicaments |
| WO2008036540A2 (en) | 2006-09-20 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| CN101605779B (zh) * | 2006-12-15 | 2013-11-20 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物 |
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| AR066379A1 (es) * | 2007-05-02 | 2009-08-12 | Boehringer Ingelheim Int | Amidas de acido carboxilico su preparacion y su uso como medicamentos |
| WO2008154441A1 (en) * | 2007-06-07 | 2008-12-18 | Joyant Pharmaceuticals, Inc. | Methods for preparing diazonamides |
| AR067329A1 (es) * | 2007-06-13 | 2009-10-07 | Bristol Myers Squibb Co | Analogos dipeptidos como inhibidores del factor de coagulacion |
| US8193177B2 (en) * | 2007-11-13 | 2012-06-05 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases |
| US8455514B2 (en) * | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| US8324199B2 (en) * | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| AU2009227013B2 (en) * | 2008-03-21 | 2013-01-10 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| WO2010044441A1 (ja) * | 2008-10-17 | 2010-04-22 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体 |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| EP2512466A4 (en) * | 2009-12-18 | 2013-07-03 | Activesite Pharmaceuticals Inc | PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN |
| ES2674745T3 (es) | 2010-02-11 | 2018-07-03 | Bristol-Myers Squibb Company | Macrociclos como inhibidores del factor XIa |
| AR082498A1 (es) * | 2010-08-20 | 2012-12-12 | Gruenenthal Gmbh | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide |
| PH12013500547A1 (en) * | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012139010A1 (en) * | 2011-04-08 | 2012-10-11 | University Of Kansas | Grp94 inhibitors |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| ES2579832T3 (es) | 2011-10-14 | 2016-08-17 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa |
| KR101937514B1 (ko) | 2011-10-14 | 2019-01-10 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물 |
| EP2766345B1 (en) | 2011-10-14 | 2016-03-16 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| GB201209138D0 (en) * | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
| GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| MX361759B (es) | 2012-08-03 | 2018-12-17 | Bristol Myers Squibb Co | Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico. |
| KR20150038369A (ko) | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 디히드로피리돈 P1 |
| WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| TR201807316T4 (tr) | 2012-10-12 | 2018-06-21 | Bristol Myers Squibb Co | Bir faktör XIa inhibitörünün kristalli formları. |
| CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| DK3811943T3 (da) | 2013-03-15 | 2023-04-03 | Aerie Pharmaceuticals Inc | Forbindelse til anvendelse til behandling af øjenlidelser |
| ES2712699T3 (es) | 2013-03-25 | 2019-05-14 | Bristol Myers Squibb Co | Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| NO2760821T3 (https=) | 2014-01-31 | 2018-03-10 | ||
| CN116987080A (zh) | 2014-01-31 | 2023-11-03 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
| US9676723B2 (en) | 2014-02-11 | 2017-06-13 | Merck Sharp & Dohme Corp | Factor XIa inhibitors |
| EP3104703B1 (en) | 2014-02-11 | 2020-11-18 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015164308A1 (en) | 2014-04-22 | 2015-10-29 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| WO2015171527A1 (en) * | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| EP3180317B1 (en) | 2014-07-28 | 2021-04-14 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| CN107074821B (zh) | 2014-09-04 | 2020-05-22 | 百时美施贵宝公司 | 为fxia抑制剂的二酰胺大环化合物 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| EP3229801B1 (en) * | 2014-12-10 | 2020-04-01 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| US9980945B2 (en) | 2015-01-13 | 2018-05-29 | Vanderbilt University | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016205482A1 (en) | 2015-06-19 | 2016-12-22 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
| ES2871111T3 (es) | 2015-07-29 | 2021-10-28 | Bristol Myers Squibb Co | Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático |
| US10287288B2 (en) | 2015-07-29 | 2019-05-14 | Bristol-Myers Squibb | Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties |
| WO2017074833A1 (en) | 2015-10-29 | 2017-05-04 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
| MX387515B (es) | 2015-10-29 | 2025-03-18 | Merck Sharp & Dohme Llc | Inhibidores de factor xia. |
| US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| EP3500556B1 (en) | 2016-08-22 | 2023-08-02 | Merck Sharp & Dohme LLC | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| HUE057289T2 (hu) * | 2016-08-31 | 2022-05-28 | Jiangsu Hengrui Medicine Co | Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| KR20190135027A (ko) | 2017-03-31 | 2019-12-05 | 에어리 파마슈티컬즈, 인코포레이티드 | 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물 |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| BR112020016856A2 (pt) * | 2018-02-27 | 2020-12-22 | Jiangsu Hengrui Medicine Co., Ltd. | Forma de cristal do derivado de oxopicolinamida e método de preparação da mesma |
| PE20210165A1 (es) * | 2018-04-10 | 2021-01-26 | Bayer Pharma AG | Un derivado de oxopiridina sustituido |
| CN120053445A (zh) | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| TWI854067B (zh) | 2019-11-26 | 2024-09-01 | 美商基利科學股份有限公司 | 預防hiv之蛋白殼抑制劑 |
| CN113683598B (zh) * | 2020-05-18 | 2022-10-14 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| PL4172157T3 (pl) | 2020-06-25 | 2026-03-23 | Gilead Sciences, Inc. | Inhibitory kapsydu w leczeniu hiv |
| DK4445900T3 (da) | 2021-12-03 | 2025-08-18 | Gilead Sciences Inc | Terapeutiske forbindelser til hiv-virusinfektion |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| JP7765637B2 (ja) | 2021-12-03 | 2025-11-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| JP7733916B2 (ja) * | 2022-02-28 | 2025-09-04 | 学校法人東海大学 | Ｃｌｅｃ－２および／またはｇｐｖｉの拮抗剤 |
| CN117143081B (zh) * | 2022-05-24 | 2025-08-01 | 赣南医科大学 | 一种Sabizabulin的制备方法 |
| CN116891472A (zh) * | 2023-07-13 | 2023-10-17 | 延边大学 | 一种含咪唑结构的酰胺类衍生物及其制备方法和应用 |
| WO2025122845A1 (en) * | 2023-12-07 | 2025-06-12 | Genep Inc. | Imidazole compounds and their use as sodium channel inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3255202A (en) * | 1963-08-23 | 1966-06-07 | Union Carbide Corp | Process for the preparation of 2-(acylamidoalkyl)benzimidazoles |
| US5618792A (en) | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
| EP0914322A1 (en) * | 1996-05-27 | 1999-05-12 | Fujisawa Pharmaceutical Co., Ltd. | New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
| EP0946587A2 (en) | 1996-12-16 | 1999-10-06 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
| US6593291B1 (en) | 1997-02-06 | 2003-07-15 | Entremed, Inc. | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| US6740682B2 (en) * | 1997-08-29 | 2004-05-25 | Tularik Limited | Meta-benzamidine derivatives as serine protease inhibitors |
| US6852725B1 (en) * | 1998-06-12 | 2005-02-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S. A. S. | Imidazolyl derivatives |
| KR20010083081A (ko) | 1998-06-30 | 2001-08-31 | 실버스타인 아써 에이. | 염증성질환, 자가면역질환 및 호흡기질환을 치료하는데유용한 브이엘에이-4-의존성 세포 결합의 비-펩티딜 억제제 |
| AU1455500A (en) | 1998-10-29 | 2000-05-22 | Trega Biosciences, Inc. | Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof |
| US6518292B1 (en) * | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
| TWI283577B (en) | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
| US7291641B2 (en) | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| WO2001032628A1 (en) | 1999-11-03 | 2001-05-10 | Bristol-Myers Squibb Pharma Company | Cyano compounds as factor xa inhibitors |
| EP1244656A1 (en) | 1999-12-28 | 2002-10-02 | Pfizer Products Inc. | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| WO2001052867A1 (en) * | 2000-01-19 | 2001-07-26 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of pentosan polysulfate to treat certain conditions of the prostate |
| AR029803A1 (es) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| ES2218391T3 (es) * | 2000-03-06 | 2004-11-16 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de raf-cinasa. |
| US7087632B2 (en) | 2001-03-05 | 2006-08-08 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
| US6414013B1 (en) * | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| WO2002010140A2 (en) | 2000-08-01 | 2002-02-07 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Imidazolyl derivatives |
| GB0021831D0 (en) | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| KR100673265B1 (ko) * | 2000-10-04 | 2007-01-22 | 엘지.필립스 엘시디 주식회사 | 액정표시장치 |
| CN100581544C (zh) | 2001-03-05 | 2010-01-20 | 美国医疗产品公司 | 用于勃起机能障碍治疗和逆转的可注射药物组合物 |
| EP1406872B1 (en) | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| WO2003035615A2 (en) | 2001-10-25 | 2003-05-01 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| DE10211770A1 (de) | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| WO2004011445A1 (ja) | 2002-07-31 | 2004-02-05 | Nippon Soda Co.,Ltd. | アミノサリチル酸アミド誘導体、製造法及び農園芸用殺菌剤 |
| KR101050700B1 (ko) * | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
| PE20040804A1 (es) * | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
| WO2004071448A2 (en) | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
| US7138412B2 (en) * | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| BRPI0407926A (pt) | 2003-03-27 | 2006-02-21 | Pfizer Prod Inc | 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas |
| JP2004323516A (ja) * | 2003-04-11 | 2004-11-18 | Nippon Soda Co Ltd | ３−アシルアミノサリチル酸アミド誘導体、製造法及び農園芸用殺菌剤 |
| US7129264B2 (en) * | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| EP1479679A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
| RS20060206A (sr) | 2003-10-01 | 2008-08-07 | Altana Pharma Ag., | Derivati aminopiridina kao inhibitori inducibilne no-sintaze |
| US7128412B2 (en) * | 2003-10-03 | 2006-10-31 | Xerox Corporation | Printing processes employing intermediate transfer with molten intermediate transfer materials |
| US7569578B2 (en) | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
| US7371743B2 (en) | 2004-02-28 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Carboxylic acid amides, the preparation thereof and their use as medicaments |
| US7453002B2 (en) * | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2006076575A2 (en) * | 2005-01-13 | 2006-07-20 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor xia inhibitors |
| EP1981854B1 (en) | 2005-12-14 | 2011-06-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
-
2005
- 2005-06-13 US US11/151,667 patent/US7453002B2/en active Active
- 2005-06-14 BR BRPI0512084-5A patent/BRPI0512084A/pt not_active IP Right Cessation
- 2005-06-14 CA CA002570472A patent/CA2570472A1/en not_active Abandoned
- 2005-06-14 JP JP2007516703A patent/JP4791460B2/ja not_active Expired - Fee Related
- 2005-06-14 WO PCT/US2005/021212 patent/WO2005123050A2/en not_active Ceased
- 2005-06-14 MX MXPA06014642A patent/MXPA06014642A/es active IP Right Grant
- 2005-06-14 KR KR1020067026365A patent/KR20070024601A/ko not_active Ceased
- 2005-06-14 RU RU2007101073/04A patent/RU2007101073A/ru not_active Application Discontinuation
- 2005-06-14 ES ES05773261.2T patent/ES2628279T3/es not_active Expired - Lifetime
- 2005-06-14 EP EP05773261.2A patent/EP1773786B1/en not_active Expired - Lifetime
- 2005-06-14 AU AU2005254102A patent/AU2005254102A1/en not_active Abandoned
-
2006
- 2006-12-05 IL IL179844A patent/IL179844A0/en unknown
- 2006-12-15 NO NO20065864A patent/NO20065864L/no not_active Application Discontinuation
-
2008
- 2008-09-12 US US12/209,235 patent/US8101778B2/en active Active
-
2011
- 2011-12-15 US US13/326,809 patent/US8716492B2/en not_active Expired - Lifetime
-
2014
- 2014-03-19 US US14/219,311 patent/US9079860B2/en not_active Expired - Lifetime
-
2015
- 2015-05-27 US US14/722,434 patent/US9617224B2/en not_active Expired - Lifetime
-
2017
- 2017-02-23 US US15/440,346 patent/US10112936B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008502700A5 (https=) | ||
| RU2007101073A (ru) | Пятичленные гетероциклы, применимые в качестве ингибиторов сериновой протеазы | |
| JP2008500284A5 (https=) | ||
| WO2006076575B1 (en) | Substituted biaryl compounds as factor xia inhibitors | |
| JP2010505881A5 (https=) | ||
| CA2478183A1 (en) | Substituted amides | |
| JP2010513304A5 (https=) | ||
| JP2007519754A5 (https=) | ||
| JP2004517080A5 (https=) | ||
| RU2003129502A (ru) | Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний | |
| JP2004508304A5 (https=) | ||
| HRP20140346T1 (hr) | DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE | |
| JP2008517976A5 (https=) | ||
| HRP20100700T1 (hr) | Vr1 benzimidazol modulatori | |
| CA2665476A1 (en) | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors | |
| RU2013138569A (ru) | Антагонисты рецептора минералокортикоидов | |
| RU2011147203A (ru) | Гетероароматические и ароматические пиперазинилазетидиниламиды в качестве ингибиторов моноацилглицеринлипазы | |
| US20070276011A1 (en) | Plasminogen Activator Inhibitor-1 Inhibitor | |
| RU2011107227A (ru) | Бензоимидазольные производные и ингибиторы гликоген-синтаза-киназы-3 бета, содержащие такие производные | |
| JP2013509376A5 (https=) | ||
| TW201712004A (zh) | 吡唑衍生物或其藥理學上容許之鹽 | |
| JP2005504093A5 (https=) | ||
| JP2016514141A5 (https=) | ||
| JP2020532589A5 (https=) | ||
| JP2004502674A5 (https=) |